Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rongrong Fu

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Frontiers in Endocrinology|June 13, 2022
Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled TrialsBin Zhou, Yetan Shi, Rongrong Fu, et al.
Journal of Pharmaceutical and Biomedical Analysis|May 9, 2024
Development of a reliable cell-based reporter gene assay to measure the bioactivity of anti-HER2 therapeutic antibodiesXiang Zhao, Weizhu Qian, Sheng Hou, et al.
Anti-Cancer Agents in Medicinal Chemistry|July 28, 2021
Efficacy of Neoadjuvant Therapy in Improving Long-Term Survival of Patients with Resectable Rectal Cancer: A Meta-AnalysisXinlong Li, Xiangyuan Li, Rongrong Fu, et al.
Pharmaceutical Development and Technology|January 17, 2024
Efficient treatment of colon cancer with codelivery of TRAIL and imatinib by liposomesRongrong Fu, Rui Chang, Andong Peng, et al.
Molecular Pharmaceutics|May 3, 2023
Codelivery of TRAIL and Mitomycin C via Liposomes Shows Improved Antitumor Effect on TRAIL-Resistant TumorsRui Chang, Rongrong Fu, Yujiao Huang, et al.
Molecular Pharmaceutics|February 7, 2025
Correction to "Codelivery of TRAIL and Mitomycin C via Liposomes Shows Improved Antitumor Effect on TRAIL-Resistant Tumors"Rui Chang, Rongrong Fu, Yujiao Huang, et al.
BMC Oral Health|November 12, 2025
Global burden and trends of common head and neck cancers between 1990 and 2021: findings from the Global Burden of Disease Study 2021Jianli Lin, Bingqin Xie, Xuehan Yi, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 3, 2024
Highly drug/target-tolerant neutralizing antibody (NAb) assay development through target-based drug depletion and drug-based NAb extraction for an anti-EGFR therapeutic monoclonal antibodyRongrong Fu, Jin Xu, Qingcheng Guo, et al.
Mbio|February 13, 2014
Heteroresistance at the single-cell level: adapting to antibiotic stress through a population-based strategy and growth-controlled interphenotypic coordinationXiaorong Wang, Yu Kang, Chunxiong Luo, et al.
Frontiers in Bioengineering and Biotechnology|April 8, 2024
Improving product quality and productivity of an antibody-based biotherapeutic using inverted frustoconical shaking bioreactorsXuekun Wang, Jin Xu, Qingcheng Guo, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Frontiers in Endocrinology|June 13, 2022
Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled TrialsBin Zhou, Yetan Shi, Rongrong Fu, et al.
Journal of Pharmaceutical and Biomedical Analysis|May 9, 2024
Development of a reliable cell-based reporter gene assay to measure the bioactivity of anti-HER2 therapeutic antibodiesXiang Zhao, Weizhu Qian, Sheng Hou, et al.
Anti-Cancer Agents in Medicinal Chemistry|July 28, 2021
Efficacy of Neoadjuvant Therapy in Improving Long-Term Survival of Patients with Resectable Rectal Cancer: A Meta-AnalysisXinlong Li, Xiangyuan Li, Rongrong Fu, et al.
Pharmaceutical Development and Technology|January 17, 2024
Efficient treatment of colon cancer with codelivery of TRAIL and imatinib by liposomesRongrong Fu, Rui Chang, Andong Peng, et al.
Molecular Pharmaceutics|May 3, 2023
Codelivery of TRAIL and Mitomycin C via Liposomes Shows Improved Antitumor Effect on TRAIL-Resistant TumorsRui Chang, Rongrong Fu, Yujiao Huang, et al.
Molecular Pharmaceutics|February 7, 2025
Correction to "Codelivery of TRAIL and Mitomycin C via Liposomes Shows Improved Antitumor Effect on TRAIL-Resistant Tumors"Rui Chang, Rongrong Fu, Yujiao Huang, et al.
BMC Oral Health|November 12, 2025
Global burden and trends of common head and neck cancers between 1990 and 2021: findings from the Global Burden of Disease Study 2021Jianli Lin, Bingqin Xie, Xuehan Yi, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 3, 2024
Highly drug/target-tolerant neutralizing antibody (NAb) assay development through target-based drug depletion and drug-based NAb extraction for an anti-EGFR therapeutic monoclonal antibodyRongrong Fu, Jin Xu, Qingcheng Guo, et al.
Mbio|February 13, 2014
Heteroresistance at the single-cell level: adapting to antibiotic stress through a population-based strategy and growth-controlled interphenotypic coordinationXiaorong Wang, Yu Kang, Chunxiong Luo, et al.
Frontiers in Bioengineering and Biotechnology|April 8, 2024
Improving product quality and productivity of an antibody-based biotherapeutic using inverted frustoconical shaking bioreactorsXuekun Wang, Jin Xu, Qingcheng Guo, et al.
Pageof 10